Eli Lilly's Foundayo (Orforglipron)—First Unrestricted Oral GLP-1—Enters U.S. Market

Eli Lilly received FDA accelerated approval on April 1 for Foundayo (orforglipron), which began LillyDirect shipments April 6 and expanded to broad pharmacy and telehealth distribution mid-April. The pill requires no meal, water or timing restrictions and showed average weight loss of 11% (approximately 25 pounds) in trials.